Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism
Authors:
- 25 March 2026
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 26 (1)
Abstract
We performed a narrative review of the literature of amyloid and tau co-pathology in Parkinson Disease and atypical parkinsonism in Pubmed database, including articles published between January 2020 to July 2025. In the last decade, different multicenter research efforts have worked to improve the accuracy of clinical-pathological diagnosis in neurogenerative disease. In this search, growing evidence from neuropathology, neuroimaging and fluid biomarkers have highlighted the role of Alzheimer's disease (AD) co-pathology in Parkinson's disease (PD) and atypical parkinsonism (AP) disorders potentially affecting progression, motor phenotype and cognitive status. Regarding studies of structural and functional imaging evidencing the presence of Amyloid-β (Aβ), tau, as co-pathologies contribute to α-synuclein-related profile of cortical atrophy, network disruption, as well as clinical heterogeneity in PD and AP disorders. In AP fluid biomarkers have shown limited diagnostic accuracy. Neuropathological evidence from systematic post-mortem surveys confirmed that diffuse and neuritic Aβ plaques are uncommon in non-demented PD (10%), intermediate in PD-dementia (30-40%), and frequent in Dementia with Lewy Bodies (60-80%). The evidence in PD and DLB showed that Aß fluid biomarkers may predict clinical trajectory and cognitive decline, while Aβ-imaging would help stratifying patients and directing therapeutic pipeline designs. In AP disorders, including progressive supranuclear palsy and corticobasal degeneration, a combined multimodal assessment of molecular imaging, structural and functional magnetic resonance with fluid biomarkers shall guarantee future differential diagnosis and prediction of clinical outcomes. Although there are no currently accepted biomarkers for PD or AP, the recent design of plasma tau biomarkers and seed-amplification assays are promising approaches which are also reviewed here.Keywords
Funding Information
- Association for Frontotemporal Degeneration (Pilot#2025-002)
- Alzheimer's Association,United States (24AACSFD-1244095)
- CurePSP (684-2023-06-Pathway)
This publication has 134 references indexed in Scilit:
- Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based BiomarkersJAMA Neurology, 2025
- Co‐pathologies modify hippocampal protein accumulation patterns in neurodegenerative diseasesAlzheimer's & Dementia, 2024
- Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear PalsyJAMA Neurology, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Relationships between PET and blood plasma biomarkers in corticobasal syndromeAlzheimer's & Dementia, 2024
- Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodiesAlzheimer's & Dementia, 2024
- Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body diseaseAnnals of Clinical and Translational Neurology, 2023
- Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy BodiesJAMA Neurology, 2021
- Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older AdultsJAMA Neurology, 2020
- Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission TomographyJAMA Neurology, 2020